Arbutus Biopharma Corporation (ABUS) Cash Flow Statement
Arbutus Biopharma Corporation (ABUS) generated -$24.6M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$24.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABUSArbutus Biopharma CorporationFollow ABUS — free
—
Price chart with a free account
- Market cap
- 831.0M
- P/E TTM
- 5.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -6.7 | -12.4 | -56.4 | -57.9 | -48.6 | -67.9 | -71.0 | -51.4 | -67.5 | -35.4 | -85.9 | -64.9 | -39.6 | -24.6 | |
| Capital expenditure | 0.7 | 1.1 | 2.3 | 4.0 | 7.3 | 1.1 | 0.6 | 0.2 | 0.8 | 0.5 | 1.0 | 0.2 | 0.0 | -0.0 | |
| Free cash flow | -7.5 | -13.5 | -58.7 | -61.9 | -55.9 | -69.0 | -71.6 | -51.7 | -68.3 | -35.9 | -86.9 | -65.0 | -39.6 | -24.6 | |
| Stock-based compensation | 0.9 | — | — | — | 15.1 | 6.2 | 6.8 | 6.2 | 6.4 | 7.2 | 9.3 | 9.0 | 7.0 | — |
USD millions · SEC XBRL
Arbutus Biopharma Corporation — questions
- What is Arbutus Biopharma Corporation's operating cash flow?
- -$24.6M over the twelve months to 2026-06-30.
- How much does Arbutus Biopharma Corporation spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Arbutus Biopharma Corporation's free cash flow?
- -$24.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Arbutus Biopharma Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.